# Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

> **NCT07714317** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** IBI310+ sintilimab + bevacizumab
- **DRUG:** IBI310+ sintilimab
- **DRUG:** sintilimab + bevacizumab

## Key facts

- **NCT ID:** NCT07714317
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2027-07-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714317, "Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07714317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*